baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. PUT 06/24 NOT/ DE000HD4FHM8 /

6/6/2024 1:46:25 PM	Chg.-	Bid2:15:27 PM	Ask6/6/2024	Underlying	Strike price	Expiration date	Option type
0.0090EUR	-	0.0090 Bid Size: 35,000	- Ask Size: 35,000	Novartis AG	90.00 -	6/19/2024	Put

GlobeNewswire 7:00 AM Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPi...

GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

TeleTrader 5/2 Novartis to acquire Mariana Oncology for $1.7B

TeleTrader 4/23 Novartis up 5% on upbeat guidance, earnings

TeleTrader 4/23 Novartis EPS up 28% to $1.31 in Q1

GlobeNewswire 4/16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...

TeleTrader 4/11 Novartis launches offer for Morphosys at €68 per share

TeleTrader 4/9 Novartis to reduce workforce by 680 in Product Development

GlobeNewswire 3/14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon

TeleTrader 3/12 Germany clears Novartis' MorphoSys $2.9B deal

TeleTrader 2/5 Novartis to acquire MorphoSys for $2.9B

TeleTrader 1/31 Novartis net sales up 8% to $11.4B in Q4

GlobeNewswire 1/10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...

GlobeNewswire 1/5 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...

GlobeNewswire 1/2 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...

GlobeNewswire 12/21/2023 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...

GlobeNewswire 12/19/2023 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...

GlobeNewswire 12/11/2023 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...

GlobeNewswire 12/8/2023 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...

GlobeNewswire 12/6/2023 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...

TeleTrader 11/28/2023 Novartis expects 5% annual sales growth until 2027

GlobeNewswire 11/20/2023 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

TeleTrader 10/24/2023 Novartis Q3 EPS up 20% to $0.73

GlobeNewswire 10/19/2023 Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search

GlobeNewswire 10/10/2023 Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

UC WAR. PUT 06/24 NOT/ DE000HD4FHM8 /

If you wish to receive reply to your feedback, please provide your email address.